Ali Vural

Serum YKL-40 levels in patients with coronary artery disease.

Atherosclerosis is considered to be an inflammatory disease in which the initial process is the augmented infiltration of monocytes into the vessel wall and their subsequent differentiation from macrophages into lipid-laden foam cells. Human cartilage glycoprotein-39 (YKL-40) is a new inflammatory marker found to be secreted by lipid-laden macrophages inside human atherosclerotic vessel wall. The aim of this study was to investigate the association of serum YKL-40 levels with the presence and extent of coronary artery disease (CAD) assessed by coronary angiography. We also studied the relation of high-sensitivity C-reactive protein with the presence and angiographic severity of CAD. A total of 200 participants undergoing to coronary angiography was divided into four subgroups: control patients without CAD (n=53), and those with one-vessel disease (n=52), two-vessel disease (n=47), or three-vessel disease (n=48). Serum YKL-40 levels were measured by enzyme-linked immunosorbent assay. Both serum YKL-40 levels and high-sensitivity C-reactive protein concentrations in patients with CAD were significantly higher than in control participants (P<0.001). We also found a significant association between the levels of YKL-40 and the extent of CAD defined by the number of stenosed vessels (P<0.001). The relationship between the serum YKL-40 level and atherosclerosis may represent a new opportunity for the possible utility of serum YKL-40 as an inflammatory marker for coronary artery disease. Moreover, our findings revealed that plasma YKL-40 measurement might also be regarded as a quantitative indicator of disease extent besides being a marker of disease presence.

The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study.

Introduction Recent studies have demonstrated the potential of microRNAs (miRNA) as biomarkers in various cardiovascular disorders. The aim of the present study was to quantitatively evaluate the expression levels of miRNAs in patients with chronic congestive heart failure (CHF) in order to identify differential expression profiles as biomarkers with prognostic values. Materials and method The study included 20 clinically stable [New York Heart Association (NYHA) II] and 22 decompensated (NYHA III and IV) CHF patients and 15 healthy controls. miRNA profiling was performed using a microarray method. Dysregulated miRNAs were evaluated for their biomarker potential. Results Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744*, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122*, miR-3148 and miR-518e* and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients. The prognostic value of miR-182 [area under the curve (AUC) 0.695] was found to be superior to pro-brain type natriuretic peptide (NT-proBNP; AUC 0.350) and high-sensitivity C-reactive protein (hs-CRP) (AUC 0.475) by receiver operator characteristic (ROC) analysis. Cox regression analysis showed that miR-182 could predict cardiovascular mortality (P = 0.032). Conclusion We demonstrated the increased expression levels of circulating miRNAs in CHF as compared with controls. Moreover, miR-182 was found to be a potential prognostic marker in CHF.

Serum myeloperoxidase level predicts reperfusion in patients with myocardial infarction receiving thrombolytic therapy

Polymorphonuclear leukocytes play a central role in all stages of the atherothrombotic inflammatory process. The atherothrombotic activity of polymorphonuclear leukocytes is exerted by mediators such as myeloperoxidase (MPO). Although the role of MPO has been studied with respect to the development of adverse cardiac events in acute coronary syndromes (ACS), the association of this molecule with effectiveness of reperfusion in patients receiving thrombolysis is not yet known. The study population consisted of a total of 158 patients with acute coronary syndromes. Final diagnosis was ST-segment elevation myocardial infarction in 86 patients, 80 of whom received thrombolysis. Blood samples were drawn at presentation of the patients and serum myeloperoxidase levels were measured. Reperfusion was defined in terms of electrocardiographic ST-segment resolution. The serum levels of MPO were found to be correlated with rates of in-hospital adverse events including death (P < 0.001), reinfarction (P < 0.001), recurrent ischemia (P < 0.001), arrhythmias (P < 0.001), clinical heart failure (P < 0.001), and cardiogenic shock (P < 0.001). There was a significant difference in serum MPO levels between subjects with three-vessel disease and two- or one-vessel disease (P < 0.001). Pre-lytic serum high-sensitivity C-reactive protein levels in patients with successful reperfusion were lower than in patients with failed reperfusion (P < 0.001). Analysis of patients with ST segment elevation myocardial infarction receiving thrombolytic therapy revealed that pre-lytic serum MPO levels in patients with successful reperfusion were significantly lower than those of patients with failed reperfusion (P < 0.001). In the present study, serum MPO levels were found to be a strong predictor of response to thrombolytic treatment in patients with ST-segment elevation myocardial infarction. Therefore the level of inflammatory activity in acute coronary syndromes seems to influence the effectiveness of fibrinolysis.

Takayasu disease with prominent pulmonary artery involvement: confusion with pulmonary disease leading to delayed diagnosis

Pulmonary artery involvement as the initial predominant clinical manifestation in Takayasu arteritis (TA) is rare. We describe a young adult female who presented with life-threatening complications of proximal pulmonary arterial involvement of Takayasu arteritis. In our case, atypical presentation of TA with pulmonary symptoms due to pulmonary artery involvement resulted in an erroneous initial diagnosis of sarcoidosis and then tuberculosis. The frequency of such a clinical form could be underestimated given the difficulties involved in its diagnosis and because its features are similar to those of pulmonary disease.

An extraordinary cause of ischemic chest pain in a young man: Congenital ostial atresia of the right coronary artery

Chest pain in a young person without cardiovascular risk factors is usually attributed to noncoronary causes; however, if the history suggests ischemic pain, the potential presence of unusual cardiovascular abnormalities should not be disregarded. The present case describes a young man with solitary congenital ostial atresia of right coronary artery, who to our knowledge is only the second case in the medical literature. Manifestation of ischemic symptoms in a relatively advanced age in patients with coronary artery atresia may mislead clinicians to interpret them as signs of atherosclerotic coronary artery disease. Therefore congenital coronary artery atresia should be a part of the differential diagnosis particularly in young patients with ischemic symptoms and no cardiovascular risk factors.

Evaluation of association between common genetic variants on chromosome 9p21 and coronary artery disease in Turkish population

Objective: Coronary artery disease (CAD), which develops from complex interactions between genetic and enviromental factors, is a leading cause of death worldwide. Based on genome-wide association studies (GWAS), the chromosomal region 9p21 has been identified as the most relevant locus presenting a strong association with CAD in different populations. The aim of the present study was to investigate the association of two SNPs on chromosome 9p21 on susceptibility to CAD and the effect of these SNPs along with cardiovascular risk factors on the severity of CAD in the Turkish population. Methods: This study had an observational case-control design. We genotyped 460 subjects, aged 30-65 years, to investigate the association of 2 SNPs (rs1333049, rs2383207) on chromosome 9p21 and CAD risk in Turkish population. Real-time polymerase chain reaction (RT-PCR) was used to analyze the 2 SNPs in CAD patients and healthy controls. The genotype and allelic variations of these SNPs with the severity of CAD was also assessed using semi-quantitative methods such as the Gensini score. Student’s t test and multiple regression analysis were used for statistical analysis. Results: The SNPs rs1333049 and rs2383207 were found to be associated with CAD with an adjusted OR of 1.81 (95% Cl 1.05-3.12) and 2.12 (95% CI 1.19-4.10) respectively. After adjustment of CAD risk factors such as smoking, family history of CAD and diabetes, the homozygous AA genotype for rs2383207 increased the CAD risk with an OR 3.69. Also a very strong association was found between rs1333049 and rs2383207 and Gensini scores representing the severity of CAD (p<0.001). Conclusion: The rs2383207 and rs1333049 SNPs on 9p21 chromosome were significantly associated with the risk and severity of CAD in the Turkish population.

The relationship between circulating microRNAs and left ventricular mass in symptomatic heart failure patients with systolic dysfunction.

BACKGROUND In recent years, many microRNAs (miRNAs) were shown to be dysregulated in specific tissues playing critical roles in the pathogenesis and progression of heart failure (HF). Left ventricular (LV) mass (LVM) has long been recognised as an important prognostic marker in systolic HF patients. AIM We hypothesised that circulating miRNAs may be associated with LVM in systolic HF patients. The present study aimed to evaluate the relationship between previously reported and novel dysregulated circulating miRNAs and echocardiographically determined LVM in symptomatic HF patients with LV systolic dysfunction. METHODS Forty-two consecutive patients diagnosed with NYHA II-IV symptomatic systolic HF and a control group consisting of 15 age- and sex-matched healthy volunteers were enrolled. After labelling extracted RNA, poly-A tails were added. RNAs were later hybridised on a GeneChip miRNA 2.0 array. After hybridisation and staining, arrays were scanned to determine miRNA expression levels, and differentially expressed miRNAs were identified. RESULTS Eighteen miRNAs were found to be upregulated in serum of HF patients, while 11 were demonstrated to be downregulated. When the association between dysregulated miRNAs and echocardiographic findings was investigated, miR-182 (p = 0.04), miR-200a* (p = 0.019), and miR-568 (p = 0.023) were found to be inversely correlated with LVM index (LVMI), while miR-155 (p = 0.019) and miR-595 (p = 0.04) were determined to be positively correlated with LVMI. CONCLUSIONS The results of our study revealed that dysregulated circulating miRNAs were correlated with anatomic changes in LV, in terms of LVMI, in symptomatic HF patients with systolic LV dysfunction.

Circulating p53 and cytochrome c levels in acute myocardial infarction patients

Background Apoptosis causes myocardiocyte loss during and after myocardial infarction. Therapeutic approaches designed to arrest apoptosis would be a significant new development in the recovery of acute myocardial infarction (AMI). In order to examine apoptotic markers in the circulation, serum levels of p53 and cytochrome c were assessed in patients with AMI. Methods Blood samples were taken on admission (before initiation of therapy) and on the 3rd and 7th days of hospitalization. Serum levels of p53 and cytochrome c were measured by enzyme-linked immunassay. Results The serum level of p53 was higher in AMI patients on admission compared to the control group. A time-dependent decrease was observed in the serum level of p53, but there was no significant change in the serum level of cytochrome c during therapy. Conclusions p53, but not cytochrome c, appears to have potential as a biomarker for reporting on apoptosis following myocardial infarction.

Factor VII levels in patients undergoing coronary angiography: factor VII and coronary artery disease.

Background Factor VII (F VII) has been widely investigated as a risk factor for coronary atherosclerosis, however there is still debate about its role in the progression of coronary artery disease (CAD). In this study F VII levels were measured in patients with angiographically proven CAD and its relation with disease severity, coronary events and with other risk factors of coronary atherosclerosis were examined. Methods Consecutive patients referred to coronary angiography were divided in three groups: 1. CAD group -those with a significant lesion in one or more coronary arteries (n = 155), 2. High-risk group - patients with normal coronary arteries and with two or more risk factors (n = 54), 3. Controls - patients with normal coronary arteries and with no or one risk factor (n = 90). CAD group was also studied according to the number of vessels involved and to the history of coronary events. Results Mean F VII levels were not different between the three groups of patients. In CAD group, F VII increased parallel to the number of vessels involved (one vessel disease: 85 ± 20%, two vessel disease: 92 ± 23%, three vessel disease: 105 ± 23%). Patients with a history of coronary events had significantly higher F VII levels than those without such a history (96 ± 25% versus 89 ± 22% respectively, P = 0.02). However, logistic regression analysis revealed no significant relation between F VII and either the presence of CAD or coronary events. Conclusions F VII levels increase in patients with previous coronary events, but it is not an independent risk factor for the progression or for the severity of CAD.

OP-020 THE RELATIONSHIP BETWEEN LYMPHOCYTE/NEUTROPHIL RATIO, MEAN PLATELET VOLUME, AND RED CELL DISTRIBUTION WIDTH AND LONG TERM CARDIOVASCULAR EVENTS IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

OP-020 THE RELATIONSHIP BETWEEN LYMPHOCYTE/NEUTROPHIL RATIO, MEAN PLATELET VOLUME, AND RED CELL DISTRIBUTION WIDTH AND LONG TERM CARDIOVASCULAR EVENTS IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION H.A. Barman, H.A. Cakmak, B. Ikitimur, A.S. Ertugrul, M. Uyar, K. Cosansu, B. Karadag, V.A. Vural. Department of Cardiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey; Department of Public Health, Selcuk University Meram Medical Faculty, Konya, Turkey; Department of Cardiology, Seka Goverment Hospital, Kocaeli, Turkey